FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169216073> ?p ?o ?g. }

• W2169216073 endingPage "5" @default.
• W2169216073 startingPage "1180" @default.
• W2169216073 abstract "BrE-3 is a murine IgG1 monoclonal antibody that binds to 97% of human ductal breast cancer specimens. A previous study documented the ability of 111In-labeled 1,4-methyl-benzyl isothiocyanate diethylenetriamine pentaacetic acid (111In-MX-DTPA) BrE-3 to specifically target breast cancer tissue in patients, and the dosimetry derived from the pharmacokinetics suggested that a useful therapeutic index could be obtained with 90Y-MX-DTPA BrE-3. A Phase I maximum tolerated dose study was, therefore, initiated.Six patients received 111In/90Y-MX-DTPA BrE-3, three of them receiving 6.25 and the other three receiving 9.25 mCi/m2 of 90Y. Pharmacokinetics, dosimetry, human anti-mouse antibody (HAMA), toxicity and clinical responses were evaluated.Three of six patients demonstrated a minor and transient, but objective tumor response, and none of the patients had significant toxicity. Tumor dosimetry ranged from 39 to 167 rad/mCi of 90Y (442-1887 rad/ dose). HAMA response occurred in five of six patients.Minimal toxicity, dosimetric calculations and clinical assessment indicate that a useful therapeutic index can be achieved with this therapy. Indium-111/yttrium-90-MX-DTPA BrE-3 can be safely administered to patients with metastatic breast cancer, and therapy doses yielded pharmacokinetics similar to those of tracer doses. Clinical responses, albeit transient, were achieved with single-dose therapy. Rapid onset of the HAMA response will hinder multicycle therapy, unless it is prevented with immunosuppressive drugs or the use of a humanized antibody. Further studies are needed to determine the optimal use of BrE-3 for radioimmunotherapy." @default.
• W2169216073 created "2016-06-24" @default.
• W2169216073 creator A5011070099 @default.
• W2169216073 creator A5018944540 @default.
• W2169216073 creator A5027594758 @default.
• W2169216073 creator A5038808449 @default.
• W2169216073 creator A5044505402 @default.
• W2169216073 creator A5046199922 @default.
• W2169216073 creator A5046589665 @default.
• W2169216073 creator A5059680487 @default.
• W2169216073 creator A5070492575 @default.
• W2169216073 creator A5085393931 @default.
• W2169216073 date "1997-08-01" @default.
• W2169216073 modified "2023-09-25" @default.
• W2169216073 title "Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial." @default.
• W2169216073 cites W1520311989 @default.
• W2169216073 cites W1537338497 @default.
• W2169216073 cites W1800548784 @default.
• W2169216073 cites W1852730062 @default.
• W2169216073 cites W1967889416 @default.
• W2169216073 cites W1980149010 @default.
• W2169216073 cites W1989071397 @default.
• W2169216073 cites W2007243185 @default.
• W2169216073 cites W2010900351 @default.
• W2169216073 cites W2015844338 @default.
• W2169216073 cites W2017381373 @default.
• W2169216073 cites W2022127749 @default.
• W2169216073 cites W2064559103 @default.
• W2169216073 cites W2083611451 @default.
• W2169216073 cites W2414172943 @default.
• W2169216073 cites W2415309604 @default.
• W2169216073 cites W2794522676 @default.
• W2169216073 cites W58400426 @default.
• W2169216073 cites W77000370 @default.
• W2169216073 cites W2483634850 @default.
• W2169216073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9255145" @default.
• W2169216073 hasPublicationYear "1997" @default.
• W2169216073 type Work @default.
• W2169216073 sameAs 2169216073 @default.
• W2169216073 citedByCount "30" @default.
• W2169216073 countsByYear W21692160732016 @default.
• W2169216073 countsByYear W21692160732018 @default.
• W2169216073 countsByYear W21692160732022 @default.
• W2169216073 crossrefType "journal-article" @default.
• W2169216073 hasAuthorship W2169216073A5011070099 @default.
• W2169216073 hasAuthorship W2169216073A5018944540 @default.
• W2169216073 hasAuthorship W2169216073A5027594758 @default.
• W2169216073 hasAuthorship W2169216073A5038808449 @default.
• W2169216073 hasAuthorship W2169216073A5044505402 @default.
• W2169216073 hasAuthorship W2169216073A5046199922 @default.
• W2169216073 hasAuthorship W2169216073A5046589665 @default.
• W2169216073 hasAuthorship W2169216073A5059680487 @default.
• W2169216073 hasAuthorship W2169216073A5070492575 @default.
• W2169216073 hasAuthorship W2169216073A5085393931 @default.
• W2169216073 hasConcept C112705442 @default.
• W2169216073 hasConcept C121608353 @default.
• W2169216073 hasConcept C126322002 @default.
• W2169216073 hasConcept C143998085 @default.
• W2169216073 hasConcept C159654299 @default.
• W2169216073 hasConcept C19831878 @default.
• W2169216073 hasConcept C203014093 @default.
• W2169216073 hasConcept C2775930923 @default.
• W2169216073 hasConcept C2776146153 @default.
• W2169216073 hasConcept C2780035454 @default.
• W2169216073 hasConcept C29730261 @default.
• W2169216073 hasConcept C2989005 @default.
• W2169216073 hasConcept C31760486 @default.
• W2169216073 hasConcept C530470458 @default.
• W2169216073 hasConcept C542903549 @default.
• W2169216073 hasConcept C71924100 @default.
• W2169216073 hasConcept C75088862 @default.
• W2169216073 hasConcept C98274493 @default.
• W2169216073 hasConceptScore W2169216073C112705442 @default.
• W2169216073 hasConceptScore W2169216073C121608353 @default.
• W2169216073 hasConceptScore W2169216073C126322002 @default.
• W2169216073 hasConceptScore W2169216073C143998085 @default.
• W2169216073 hasConceptScore W2169216073C159654299 @default.
• W2169216073 hasConceptScore W2169216073C19831878 @default.
• W2169216073 hasConceptScore W2169216073C203014093 @default.
• W2169216073 hasConceptScore W2169216073C2775930923 @default.
• W2169216073 hasConceptScore W2169216073C2776146153 @default.
• W2169216073 hasConceptScore W2169216073C2780035454 @default.
• W2169216073 hasConceptScore W2169216073C29730261 @default.
• W2169216073 hasConceptScore W2169216073C2989005 @default.
• W2169216073 hasConceptScore W2169216073C31760486 @default.
• W2169216073 hasConceptScore W2169216073C530470458 @default.
• W2169216073 hasConceptScore W2169216073C542903549 @default.
• W2169216073 hasConceptScore W2169216073C71924100 @default.
• W2169216073 hasConceptScore W2169216073C75088862 @default.
• W2169216073 hasConceptScore W2169216073C98274493 @default.
• W2169216073 hasIssue "8" @default.
• W2169216073 hasLocation W21692160731 @default.
• W2169216073 hasOpenAccess W2169216073 @default.
• W2169216073 hasPrimaryLocation W21692160731 @default.
• W2169216073 hasRelatedWork W1975762038 @default.
• W2169216073 hasRelatedWork W2127950213 @default.
• W2169216073 hasRelatedWork W2146102943 @default.
• W2169216073 hasRelatedWork W2169216073 @default.

• next